Compare AbCellera Biologics Inc (ABCL) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs BlackRock TCP Capital Corp — how do they compare? AbCellera Biologics Inc trades at $9.94 (market cap $2.99B), while BlackRock TCP Capital Corp trades at $3.92 (market cap $327.64M). The key difference: AbCellera Biologics Inc is far larger — about 9.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TCPC | |
|---|---|---|
Market Cap | $2.99B | $327.64M |
Sector | Health | Financials |
52-Week High | $9.76 | $7.26 |
52-Week Low | $2.78 | $3.13 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
TCPC trades at $3.88, down 1.52% today, with a bullish technical trend and neutral oscillators. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company announced a $523 million portfolio sale to reduce leverage. The stock shows a high P/S ratio of 70.7 but trades below book value with a P/B of 0.59. Dividends of $0.17 per share are scheduled for H1 and H2 2026.
Outlook is mixed: strategic moves and dividend yield near 8.8% offer value, but negative revenue, net losses, and a class action lawsuit pose risks. Analyst consensus leans hold, with 30.8% buy ratings. Further upside depends on successful execution of the strategic review and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
